Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RX 10045

Drug Profile

RX 10045

Alternative Names: RvE1 synthetic analogue; RX-10045

Latest Information Update: 03 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Resolvyx Pharmaceuticals
  • Developer Auven Therapeutics; Resolvyx Pharmaceuticals
  • Class Eye disorder therapies; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Inflammation mediator inhibitors; Lipid modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Postoperative inflammation; Postoperative pain
  • Preclinical Age-related macular degeneration; Diabetic macular oedema
  • No development reported Allergic conjunctivitis; Dry eyes; Retinal disorders

Most Recent Events

  • 03 Oct 2018 RX 10045 is still in phase II trials for Postoperative inflammation and Postoperative pain in USA (Auven Therapeutic's pipeline - October 2018)
  • 10 Sep 2018 No development reported - Phase-II for Postoperative inflammation in USA (Ophthalmic)
  • 10 Sep 2018 No development reported - Phase-II for Postoperative pain in USA (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top